Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detectionBARUZZI, A; CONTIN, M; ALBANI, F et al.Journal of chromatography. 1986, Vol 375, Num 1, pp 165-169, issn 0021-9673Article

High-performance liquid chromatographic determination of amantadine in urine after micelle-mediated pre-column derivatization with 1-fluoro-2,4-dinitrobenzeneVAN DER HORST, F. A. L; TEEUWSEN, J; HOLTHUIS, J. J. M et al.Journal of pharmaceutical and biomedical analysis. 1990, Vol 8, Num 8-12, pp 799-804, issn 0731-7085, 6 p.Conference Paper

Carbidopa dosage modifies L-DOPA induced side effects and blood levels of L-DOPA and other aminoacids in advanced parkinsonismPAREJA, F. B; MARTINEZ-MARTIN, P; MURADAS, V et al.Acta neurologica scandinavica. 1985, Vol 72, Num 5, pp 506-511, issn 0001-6314Article

More on ciladopa. ReplySNIDER, S. R; AMINOFF, M. J; GOODIN, D. S et al.Annals of neurology. 1987, Vol 22, Num 4, issn 0364-5134, 558Article

Metabolism of carbidopa to alpha-methyldopamine and alpha-methylnorepinephrine in ratsSHELTON, R. C; FAROUK KAROUM; LIN-WHEI CHUANG et al.Biochemical pharmacology. 1985, Vol 34, Num 20, pp 3623-3626, issn 0006-2952Article

Traitement de la maladie de Parkinson = Parkinson disease treatmentGUILLARD, A.Concours médical (Paris). 1986, Vol 108, Num 26, pp 2173-2178, issn 0010-5309Article

Spectrophotometric method for the determination of carbidopa using neotetrazolium chlorideISSOPOULOS, P. B; ECONOMOU, P. T.Journal of pharmacy and pharmacology. 1992, Vol 44, Num 12, pp 1020-1022, issn 0022-3573Article

Accidents de sevrage médicamenteux antiparkinsoniens et neuroleptiques = Antiparkinsonian and neuroleptic drugs: withdrawal complicationsMIZON, J. P; ROSA, A.Thérapie (Paris). 1984, Vol 39, Num 4, pp 421-425, issn 0040-5957Article

Dopa responsive dystonia: a treatable condition misdiagnosed as cerebral palsyBOYD, K; PATTERSON, V.British medical journal (1857). 1989, Vol 298, Num 6679, pp 1019-1020, issn 0007-1447, 2 p.Article

Wirkung eines neuen Antiparkinsonmittels, Selegilin, auf die psychomotorische Leistungsfähigkeit des Menschen = Effet d'un nouvel antiparkinsonien, Sélégine sur les performances psychomotrices chez l'homme = Effect of a new antiparkinson drug, Selegine, on psychomotor performance in humansMÜLLER-LIMMROTH, W.Arzneimittel-Forschung. 1985, Vol 35, Num 6, pp 998-1002, issn 0004-4172Article

Spectrophotometric determination of microquantities of Carbidopa using the Carbidopa-iron(III)-phenylfluorone ternary complex in micellar mediumISSOPOULOS, P. B; ECONOMOU, P. T.Fresenius' journal of analytical chemistry. 1992, Vol 343, Num 6, pp 518-522, issn 0937-0633Article

Einfaches fotometrisches Verfahren zur Bestimmung von L-Dopa und Carbidopa in Arzneizubereitungen = Dosage de la L-Dopa et de la Carbidopa dans les formes pharmaceutiques par photométrie = Simple photometric method for the determination of L-Dopa and Carbidopa in drug preparationsSTEUP, A; METZNER, J; VOLL, A et al.Pharmazie. 1986, Vol 41, Num 10, issn 0031-7144, 739Article

Existe-t-il un syndrome de sevrage spécifique aux antiparkinsoniens non dopaminergiques? = Does a specific withdrawal syndrome from non dopaminergic antiparkinsonian drugs exist?GEORGE, V; CASTOT, A; BIDAULT, I et al.Thérapie (Paris). 1987, Vol 42, Num 4, pp 339-341, issn 0040-5957Conference Paper

The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of ParkinsonismNUTT, J. G; WOODWARD, W. R; ANDERSON, J. L et al.Annals of neurology. 1985, Vol 18, Num 5, pp 537-543, issn 0364-5134Article

Distribution of amantadine-resistant H5N1 avian influenza variants in AsiaCHEUNG, Chung-Lam; RAYNER, Jane M; HONGLIN CHEN et al.The Journal of infectious diseases. 2006, Vol 193, Num 12, pp 1626-1629, issn 0022-1899, 4 p.Article

Neurotoxic and neurotrophic effects of L-DOPA on dopamine neuronsMENA, M. A; CASAREJOS, M. J; GARCIA DE YEBENES, J et al.Recent research developments in neurochemistry (Vol. 2 (1999) ; part I). 1999, pp 91-97, isbn 81-86481-99-0Book Chapter

Reappraisal of temporary levodopa withdrawal (drug holiday) in Parkinson's diseaseMAYEUX, R; STERN, Y; MULVEY, K et al.The New England journal of medicine. 1985, Vol 313, Num 12, pp 724-728, issn 0028-4793Article

Influence of L-DOPA/carbidopa on pattern reversal VEP: behavioural differences in primary and secondary parkinsonismSOLLAZZO, D.Electroencephalography and clinical neurophysiology. 1985, Vol 61, Num 4, pp 236-242, issn 0013-4694Article

In vitro identification of the cytochrome P450 isoform responsible for the metabolism of α-dihydroergocryptineALTHAUS, M; RETZOW, A; CASTELL, J. V et al.Xenobiotica (London. Print). 2000, Vol 30, Num 11, pp 1033-1045, issn 0049-8254Article

Accès soudains de sommeil sous ropinirole = Sudden sleep accesses under ropinirolLa Revue Prescrire. 2000, Vol 20, Num 202, issn 0247-7750, p. 35Article

Les antiparkinsoniens anticholinergiques = The anticholinergic antiparkinson agentsTAURAND, S.Soins. 1996, Num 605, issn 0038-0814, p. 61Article

L-dopa abuse in a patient with former alcoholismSOYKA, M; HUPPERT, D.British journal of addiction (1980). 1992, Vol 87, Num 1, pp 117-118, issn 0952-0481Article

The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans : a personal viewKNOLL, J.Pharmacology & toxicology. 1992, Vol 70, Num 5, pp 317-321, issn 0901-9928, 1Article

Médicaments à poursuivre ou à interrompre avant une anesthésie. I = Drugs to continue or to stop before an anesthesia. ICHAUVIN, M.Concours médical (Paris). 1988, Vol 110, Num 26, pp 2267-2270, issn 0010-5309Article

Neuroleptic malignant syndrome in striatonigral degenerationGIBB, W. R. G.British journal of psychiatry (Print). 1988, Vol 153, pp 254-255, issn 0007-1250Article